Pyrilutamide is a topical androgen receptor antagonist that was discovered during the process of developing an anti-prostate cancer drug. It works by blocking testosterone and DHT from binding with the androgen receptor in hair follicles.
It is manufactured by Kintor Pharmaceuticals and undergoing phase II clinical trials for androgenic alopecia in China and the US. The trial is a randomized, double-blind, placebo-controlled, dose-escalation study.
Buy Pyrilutamide is an androgen receptor antagonist. It works by blocking testosterone and DHT from binding with the androgen receptors in the follicles. This prevents the hair follicles from producing new hair and helps prevent hair loss. It also improves the appearance of existing hair and prevents further damage to existing follicles. It is a topical medication and can be applied to the scalp twice a day.
The compound has been tested in a small phase II trial. It was found to be effective in reducing androgenic alopecia in men with less side effects than other treatments. Kintor Pharma plans to conduct a larger, phase III trial of this drug in China.
The results of this trial will give us a better idea of how well this treatment works. The company has already enrolled 740 patients in the trial. The resulting data will be presented at a high-profile conference in 2022. Hopefully, this drug will be an effective alternative for those who have had bad experiences with finasteride and RU58841.
Pyrilutamide is an androgen receptor antagonist, which was accidentally discovered by Kintor Pharma during research for a prostate cancer drug. Apparently, overactive androgen receptors are also the cause of hair loss and acne.
Unlike Minoxidil, which has limited efficacy and side effects such as libido loss and orthostatic hypotension, or Finasteride, which may result in erectile dysfunction, Pyrilutamide is a much more potent anti-androgen. Moreover, it doesn’t have any serious adverse reactions.
The drug is currently in phase II clinical trials in the US and China for the treatment of male and female androgenetic alopecia. Its potential as a first-in-class topical AR antagonist makes it the most exciting development in hair loss treatments since finasteride.
Pyrilutamide works by blocking testosterone and dihydrotestosterone (DHT), which is the main androgen that causes the hairs to thin. In addition, it has a very short half-life, making it suitable for topical use. Moreover, it has an excellent safety profile based on completed clinical trials.
Buy Pyrilutamide in Europe (KX-826) is a high potency androgen receptor antagonist developed by Kintor Pharma for the treatment of androgenic alopecia and acne. This topical compound has shown great promise in phase II clinical trials and is the most effective androgenic alopecia drug available.
The topical application of pyrilutamide makes it a more appealing option than oral medication. It also has a much lower risk of serious side effects. In phase 2 clinical trials the only reported side effect was contact dermatitis, which can easily be corrected by switching to a different solution.
Kintor recently announced a US phase 2 trial for their new hair loss drug pyrilutamide, and it’s expected to begin next year. This is a big deal because if this drug is as effective as the results from its phase 2 China trial, it could be a game changer for AGA. We’ll know more after the data is read out later this year.
Pyrilutamide, also known as KX-826 is a promising hair treatment with excellent efficacy and good safety profile based on completed clinical trials. It blocks testosterone and DHT from binding with the androgen receptor in the follicle thereby blocking hair growth. It is expected to be a great addendum to the current FDA-approved hair treatments Minoxidil and Finasteride.
It is being developed by Kintor Pharmaceuticals a biotechnology company focused on developing and commercializing innovative treatments for diseases with unmet medical needs like androgenic alopecia, acne vulgaris and prostate cancer. The Company’s development program is supported by phase Ib clinical trial results in the United States.
The raw material used in this formulation is >99% pure and has been tested by a 3rd party lab. It is delivered in a propylene glycol and ethanol vehicle for ease of application. The solution can be stored for a long period of time, however, it should be kept in a dark area as exposure to light will degrade the active ingredient.